Skip to content
Biodatica
Start free

Eikon Therapeutics

Daphne, Alabama

OncologyPhase IIIListed · EIKN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

7w agoTrial registeredMay 28, 2026Source filing (opens the source filing in a new tab)

Momentum

77no change

Momentum 77 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2/PHASE3 registered

    May 22, 2025

    Advanced Melanoma · RECRUITING · sponsor: Eikon Therapeutics · Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

    ClinicalTrials.gov · NCT06697301 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Feb 6, 2024

    NSCLC · ACTIVE_NOT_RECRUITING · sponsor: Eikon Therapeutics · A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

    ClinicalTrials.gov · NCT06246110 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources